CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project explores the role of the TRIB2 protein in drug resistance in melanoma, a severe skin cancer. It aims to understand how TRIB2 contributes to resistance against MEK inhibitors and to develop it as a biomarker for personalized treatment strategies.
Melanoma is the most aggressive form of skin cancer resistant to all standard therapies.
Currently, the established treatment of metastatic melanoma includes dacarbazine (DTIC) administration associated with response rates of between 10-20% with severe side effects during treatment.
Recently, the BRAF inhibitors (vemurafenib and dabrafenib) and the MEK inhibitor (trametinib) were approved for the treatment of melanoma patients with mutated BRAF (about 50% of patients) while there are several PI3…
UNIVERSIDADE DO ALGARVE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
